Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PharmaCyte Biotech ( (PMCB) ) has provided an update.
On March 30, 2026, PharmaCyte Biotech, Inc. held its annual meeting of stockholders via live webcast, with about 55% of eligible shares represented, and shareholders elected five directors to serve until the 2027 meeting while ratifying CBIZ CPAs P.C. as the independent auditor for the fiscal year ending April 30, 2026 and approving, on an advisory basis, the compensation of named executive officers. Investors also authorized the board to implement a reverse stock split at a ratio between 1-for-1.1 and 1-for-100 if needed and approved an amendment to the 2022 Equity Incentive Plan that increases the pool of shares available for equity awards by 2,000,000, decisions that enhance the company’s flexibility in capital management, corporate governance, and employee and executive incentives.
These outcomes reflect shareholders’ support for PharmaCyte Biotech’s current leadership and financial oversight while positioning the company to adjust its share structure and strengthen equity-based compensation, which may affect future dilution, trading dynamics, and the firm’s ability to compete for talent in the biotechnology sector.
More about PharmaCyte Biotech
PharmaCyte Biotech, Inc. is a biotechnology company whose activities center on developing therapies within the life sciences and healthcare sector. Its capital structure and governance are closely watched by investors, with equity incentive plans and board composition playing a key role in how it attracts and retains executive and scientific talent in a competitive biotech market.
Average Trading Volume: 236,670
Technical Sentiment Signal: Sell
Current Market Cap: $7.4M
Learn more about PMCB stock on TipRanks’ Stock Analysis page.